Mario Roncadin
Czech Radio
67 Papers
458 Citations
Mario Roncadin is an academic researcher from Czech Radio. The author has contributed to research in topics: Radiation therapy & Breast cancer. The author has an hindex of 20, co-authored 67 publications. Previous affiliations of Mario Roncadin include University of Mannheim.
Chat about Author
Papers
Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial
Jayant S. Vaidya,Jayant S. Vaidya,Frederik Wenz,Max Bulsara,Jeffrey S Tobias,David Joseph,Mohammed Keshtgar,Henrik Flyger,Samuele Massarut,Michael Alvarado,Christobel Saunders,Christobel Saunders,Wolfgang Eiermann,M Metaxas,Elena Sperk,Marc Sütterlin,Douglas Brown,Laura J. Esserman,Mario Roncadin,Alastair M. Thompson,John Dewar,H Holtveg,Steffi Pigorsch,Mary Falzon,Eleanor E.R. Harris,A Matthews,Chris Brew-Graves,Ingrid Potyka,Tammy Corica,Norman R. Williams,Michael Baum +30 more
TL;DR: 5-year results for local recurrence and the first analysis of overall survival are reported and complications and mortality were much the same between groups but grade 3 or 4 skin complications were significantly reduced with TARGIT.
849
Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial
Jayant S. Vaidya,David Joseph,Jeffrey S Tobias,Max Bulsara,Frederik Wenz,Christobel Saunders,Christobel Saunders,Michael Alvarado,Henrik Flyger,Samuele Massarut,Wolfgang Eiermann,Mohammed Keshtgar,John Dewar,Uta Kraus-Tiefenbacher,Marc Sütterlin,Laura J. Esserman,H Holtveg,Mario Roncadin,Steffi Pigorsch,M Metaxas,Mary Falzon,A Matthews,Tammy Corica,Norman R. Williams,Michael Baum +24 more
TL;DR: For selected patients with early breast cancer, a single dose of radiotherapy delivered at the time of surgery by use of targeted intraoperative radiotherapy should be considered as an alternative to external beam radiotherapydelivered over several weeks.
781
Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer
Arne Wallgren,Jacques Bernier,Richard D. Gelber,Aron Goldhirsch,Mario Roncadin,David J. Joseph,Monica Castiglione-Gertsch +6 more
TL;DR: Evaluation of outcomes for patients who received breast irradiation after completing different durations of chemotherapy found no differences in the 4-year actuarial total failure rates, risk of developing distant metastases, and overall survival among the two radiotherapy groups of each study.
97
Targeted intraoperative radiotherapy (TARGIT) yields very low recurrence rates when given as a boost
Jayant S. Vaidya,Michael Baum,Jeffrey S Tobias,Samuele Massarut,Frederik Wenz,Olive Murphy,Basil S. Hilaris,Joan Houghton,Christobel Saunders,Tammy Corica,Mario Roncadin,Uta Kraus-Tiefenbacher,Frank Melchaert,Mohammed Keshtgar,Richard Sainsbury,Michael Douek,Elly Harrison,Alastair M. Thompson,David Joseph +18 more
TL;DR: Targeted intraoperative radiotherapy combined with EBRT results in a low local recurrence rate, which supports the need for a randomized trial to test whether the TARGIT boost is superior to conventional external boost, especially in high-risk women.
Expression of myelomonocytic antigens is associated with unfavourable clinicoprognostic factors in B-cell chronic lymphocytic leukaemia
Antonio Pinto,L Del Vecchio,Anna Carbone,Mario Roncadin,R. Volpe,Diego Serraino,S. Monfardini,Alfonso Colombatti,Vittorina Zagonel +8 more
TL;DR: The results indicate for the first time a statistically significant association of CD13, CD11c, and CD11b antigens with unfavourable prognostic factors in B-CLL and suggest that the cross-lineage expression of myeloid-associated surface peptidase and/or cell adhesion molecules may influence the biological and clinical behaviour of chronic lymphoproliferative disorders of B cells.
68